CATX Latest Press Releases

-- October 23, 2026 --

Perspective's [212Pb]Bamzireotide Navoxetan (VMT-a-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs Globe Newswire 10:49 AM

-- October 8, 2026 --

Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 for the Treatment of Adult Patients with Locally Advanced Unresectable and/or Metastatic FAP-Positive Solitary Fibrous Tumors Globe Newswire 6:16 AM

-- October 7, 2026 --

Perspective Therapeutics Announces Acceptance of [212Pb]VMT-a-NET Data for Presentation at the NANETS 2026 Multidisciplinary NET Medical Symposium Globe Newswire 6:16 AM

-- October 2, 2026 --

Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026 Globe Newswire 11:46 AM

-- September 14, 2026 --

Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda (Pembrolizumab) in FAP-a Positive Solid Tumors Globe Newswire 6:16 AM

-- September 11, 2026 --

Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 Globe Newswire 6:00 AM

-- August 10, 2026 --

Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results Globe Newswire 4:22 PM

-- July 31, 2026 --

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2026 Financial Results Globe Newswire 6:30 AM

-- July 28, 2026 --

Perspective Therapeutics Receives European Orphan Medicinal Product Designation for [212Pb]VMT-a-NET in GEP-NETs Globe Newswire 6:30 AM

-- July 17, 2026 --

Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Oral Presentation at the ESMO Congress 2026 Globe Newswire 12:22 PM

-- July 8, 2026 --

Perspective Therapeutics Appoints Paul Lyne, Ph.D., as Chief Science Officer; Co-Founder Michael K. Schultz, Ph.D., Transitions to Senior Scientific Advisor Globe Newswire 6:30 AM

-- June 3, 2026 --

Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-a-NET in the Meningioma Cohort of a Phase 1/2a Study Globe Newswire 6:30 AM

Market Data Delayed 15 Minutes